C3d‐positive donor‐specific antibodies have a role in pretransplant risk stratification of cross‐match‐positive HLA‐incompatible renal transplantation : United Kingdom multicentre study by Babu, Adarsh et al.
ORIGINAL ARTICLE
C3d-positive donor-specific antibodies have a role
in pretransplant risk stratification of cross-match-
positive HLA-incompatible renal transplantation:
United Kingdom multicentre study
Adarsh Babu1,2 , Natasha Khovanova3, Olivia Shaw4, Sian Griffin5, David Briggs6, Nithya S. Krishnan2,
Simon Fletcher2, Christopher Imray1,2, Adrienne Seitz7,8, Richard Baker8, Matthew Wellberry-Smith8,
Brendan Clarke7, Katherine Cullen7, Tracey Rees9, Frankie Edwards9, Emma Burrows9, Louise Howe3,
Chloe Martin3, Anthony Dorling10, Daniel Zehnder1,11, Robert M. Higgins1,2, Daniel A. Mitchell1 &
Sunil Daga1,8
1 Warwick Medical School,
University of Warwick, Coventry, UK
2 Renal Medicine and
Transplantation, University Hospitals
Coventry and Warwickshire NHS
Trust, Coventry, UK
3 School of Engineering, University
of Warwick, Coventry, UK
4 Department of Histocompatibility
and Immunogenetics, Viapath,
London, UK
5 Department of Renal Medicine
and Transplantation, University of
Wales Hospital, Cardiff, UK
6 NHS Blood and Transplant,
Birmingham, UK
7 Department of Histocompatibility
and Immunogenetics, Leeds
Teaching Hospital NHS Trust, Leeds,
UK
8 Department of Nephrology and
Transplantation, St James’s
University Hospital,Leeds Teaching
Hospital NHS Trust, Leeds, UK
9 Welsh Transplantation and
Immunogenetics Laboratory, Cardiff,
UK
10 Department of Renal Medicine
and Transplantation, Guys and St
Thomas NHS Foundation Trust,
London, UK
11 Department of Nephrology/
Acute Medicine, North Cumbria
University Hospital NHS Trust,
Carlisle, UK
ABSTRACT
Anti-HLA-antibody characteristics aid to risk-stratify patients and improve
long-term renal graft outcomes. Complement activation by donor-specific
antibody (DSA) is an important characteristic that may determine renal
allograft outcome. There is heterogeneity in graft outcomes within the
moderate to high immunological risk cases (cross-match-positive). We
explored the role of C3d-positive DSAs in sub-stratification of cross-
match-positive cases and relate to the graft outcomes. We investigated 139
cross-match-positive living-donor renal transplant recipients from four
transplant centres in the United Kingdom. C3d assay was performed on
serum samples obtained at pretreatment (predesensitization) and Day 14
post-transplant. C3d-positive DSAs were found in 52 (37%) patients at
pretreatment and in 37 (27%) patients at Day 14 post-transplant. Median
follow-up of patients was 48 months (IQR 20.47–77.57). In the multivari-
able analysis, pretreatment C3d-positive DSA was independently associated
with reduced overall graft survival, the hazard ratio of 3.29 (95% CI 1.37–
7.86). The relative risk of death-censored five-year graft failure was 2.83
(95% CI 1.56–5.13). Patients with both pretreatment and Day 14 C3d-pos-
itive DSAs had the worst five-year graft survival at 45.5% compared with
87.2% in both pretreatment and Day 14 C3d-negative DSA patients with
the relative risk of death-censored five-year graft failure was 4.26 (95% CI
1.79, 10.09). In this multicentre study, we have demonstrated for the first
time the utility of C3d analysis as a distinctive biomarker to sub-stratify
the risk of poor graft outcome in cross-match-positive living-donor renal
transplantation.
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Introduction
It is known for the past five decades that the pres-
ence of complement-activating anti-graft antibodies
results in reduced graft survival and precludes trans-
plantation [1]. Early attempts at renal transplantation
across antibody barriers have improved access to
transplantation for highly sensitized patients [2-4].
Refinement of desensitization protocols has led to bet-
ter survival for these patients compared with remain-
ing on dialysis [5-8]. However, even with significant
progress in desensitization immunotherapies, highly
sensitized patients wait longer. Approximately thirty
per cent of patients on the waiting list for deceased-
donor organs are highly sensitized and have calculated
panel reactive antibodies (cPRA)>20% [9]. Recipients
who have undergone HLA-incompatible transplants
are at higher risk for both acute antibody-mediated
rejection (ABMR) and shortened graft survival com-
pared with those who have received compatible or
ABO-incompatible transplants. Despite advances in
immune-monitoring technologies, uncertainties with
pretransplant risk stratification prevail. CDC-positive
cross-match is associated with the highest risk of both
an ABMR and graft failure. The risk is lesser if the
DSA is detectable only by FC cross-match and the
risk falls further in cross-match-negative cases, where
DSA is detected by single-antigen bead (SAB) analysis
[10-12]. Graft failure is usually related to chronic
antibody-mediated injury[11,13-15].
Numerous investigations have begun to establish
the role of DSA in mediating renal allograft rejection
and graft survival [14,16,17]. We have previously
shown that following HLA-incompatible transplanta-
tion, anamnestic responses peak at around 14 days
post-transplant and the risk of acute ABMR is higher
with DSA MFI> 7000 [18]. Anti-HLA subclasses IgG1
and IgG3 strongly activate complement and have the
potential to serve as predictors of rejection and allo-
graft survival [19-21]. The field of antibody testing
has evolved, and it is possible to study the comple-
ment proteins and split products on solid-phase
assays using isolated HLA proteins [22-24]. The
advancements in immune monitoring emphasize the
need to investigate the role of DSA that activates the
complement cascade in the highly sensitized patients
with positive cross-match, both pretreatment and fol-
lowing early transplantation. Awareness of the pres-
ence of complement-activating DSA could potentially
enable effective risk stratification of cross-match-posi-
tive patients as well as the prediction of ABMR.
However, studies in standard or low immunological
risk (cross-match-negative) patients, complement-fixing
assays have shown conflicting results in risk stratifica-
tion for ABMR and graft survival[23,25-30]. In this
multicentre study, we investigated the role of pretreat-
ment and early post-transplant complement-activating
DSA (as measured by C3d assay) to aid in further
risk stratification of moderate to high immunological
risk (positive cross-match) cases, for renal allograft
survival.
Concise materials and methods
Study design
This analysis comprises a United Kingdom multicentre
retrospective cohort study of patients who underwent
HLA-antibody-incompatible renal transplants at four
University Hospital centres: University Hospitals Coven-
try and Warwickshire (UHCW); Guy’s Hospital, Lon-
don; University Hospital of Wales (UHW, Cardiff), and
Leeds Teaching Hospitals (LTH). Ethics committee
approved the study (Ethics reference number is CREC-
055/01/03 and 13/WM/0090). Clinical and research
activities abide by the 2013 Declaration of Helsinki and
the 2008 Declaration of Istanbul.
All of the following inclusion criteria were met
the following: recipients of living-donor HLA-anti-
body-incompatible transplants with pretransplant
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plasmapheresis; CDC and/or FC cross-match positive
and DSA positive by SAB before desensitization
therapy.
The exclusion criteria were the following: recipients
with DSA detected by SAB alone (i.e. cross-match nega-
tive) that did not require pretransplant plasmapheresis;
dual HLA and ABO-incompatible renal transplants; pae-
diatric renal transplant recipients (age < 18 years); and
primary nonfunction of the graft.
One hundred and ninety-nine recipients received
antibody-incompatible renal transplants between 2005
and 2015 at the four transplant centres, of whom 139
met the inclusion criteria and comprised the final study
cohort. We analysed pretreatment (pretransplant sample
before plasmapheresis and/or IVIG) and Day 14 samples
[18,31-33]. Pretreatment serum samples were available
for 139 recipients, but post-transplant Day 14 samples
were only available for 111 recipients.
HLA typing and antibody testing
Histocompatibility and immunogenetics laboratory per-
formed the HLA typing and serological testing. HLA
types were determined by DNA-based methods for
HLA-A, B, C, DR, DPB and DQB alleles. CDC (without
AHG enhancement) and FC assays were performed as
published in our previous study [13]. CDC cross-match
was performed only in three of the four centres. All the
stored pretreatment serum samples were tested for IgG
antibodies at a final dilution of 1:5 as per the manufac-
turer guidelines (Lifecodes, Immucor, UK) and other
published literature [28,34]. This technique reduced the
commonly encountered problem of high-dose hook
effect [34]. The detailed method is described in the
Appendix S1. Data acquired with Luminex version 2.3
were analysed with MatchIT software provided by the
manufacturer.
C3d analysis
The C3d analysis was performed with the C3d assay kit
(Lifecodes, Immucor). Both pretreatment and Day 14
samples were tested for C3d deposition on the HLA sin-
gle-antigen beads as per manufacturer guidelines. C3d
data acquired with Luminex version 2.3 were analysed
with MatchIT software provided by the manufacturer.
Desensitization protocol
Patients with positive CDC and/or positive FC cross-
match against their donors typically underwent between
three and seven sessions of plasmapheresis with or with-
out IVIG to render them CDC and/or FC cross-match
negative at the time of the transplant. Desensitization
protocols, induction agent and maintenance immuno-
suppression followed at the four centres are summarized
in Table S2.
Rejection episodes were diagnosed with renal biopsy
findings in line with contemporary Banff criteria [35-
37]. In eight cases where the biopsy was precluded
for reasons such as anticoagulation, patient refusal,
the diagnosis of ABMR was based on clinical findings
(drop in urine output with rising creatinine) and the
laboratory data (rapidly rising DSA levels). ABMR
episodes within the first-month post-transplant were
considered as early ABMR. Rejection episodes were
treated initially with intravenous methylprednisolone.
Other treatment for ABMR included rATG (21
patients), plasmapheresis and IVIG (3 patients), and
two recipients with refractory ABMR received ritux-
imab and eculizumab.
Statistical analysis
Statistical analysis was performed using the Pearson chi-
square test for categorical variables. Normality of data
was tested using the Shapiro–Wilk test. Independent
samples t-test and Mann–Whitney U-test were used for
continuous data depending on the distribution of data.
Multivariable analysis for medium-term survival out-
come was carried out using Cox proportional hazard
models. We chose three different models to determine
the independent role of C3d DSA after adjusting for
variables. IgG DSA variable was studied differently in
the models (In Model 1 – continuous variable, Models
2 and 3 – as a categorical variable with different cut-offs
of 8000 and 5000). The IgG DSA arbitrary cut-offs were
based on association with FC or CDC reactivity at our
centres. IgG DSA cut-off ≥ 8000MFI is associated with
higher positive predictive value for positive CDC cross-
match [38,39]
Kaplan–Meier survival analysis and adjusted death-
censored graft survival analysis were carried out after
adjusting for age, gender, duration on dialysis, mis-
match, previous transplantation and ABMR. Groups
were compared based on the log-rank test. For clinical
relevance, relative risks for death-censored five-year
graft failures were computed using an online calculator
for effect size measures [40]. The null hypothesis of no
difference between the groups of interest was tested at
the 5% significance level. Calculations were performed
using SPSS V24 (Chicago, IL).
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Results
Characteristics of the study population
The characteristics of the 139 recipients are presented in
Table 1. The median follow-up time was 48 months
(IQR 20.47–77.57). Fifty-two (37%) pretreatment and
thirty-seven (27%) post-transplant cases had C3d-posi-
tive DSA. Characteristics that were associated with a
higher proportion of C3d-positive DSAs included
younger age, male gender, longer dialysis duration and
patients with previous transplants. There were no signif-
icant differences between the groups with regard to
immunosuppression at induction apart from a higher
proportion of cases with C3d-positive DSA receiving
rATG, but overall numbers were low. Pretreatment
C3d-positive DSA was associated with higher IgG DSA
MFI and was predominantly HLA class II antibodies.
Thirty-five grafts failed over the entire period of whom
pretreatment C3d-positive DSA was present in twenty-
two cases (Table S3). Six patients died with functioning
grafts during the follow-up. None of these patients had
pretreatment C3d-positive DSA. Only one patient had
Day 14 C3d-positive DSA.
C3d analysis and renal allograft survival
Over the study period, thirty-five (25%) grafts were lost.
Twenty-nine cases had renal biopsy features consistent
with chronic antibody-mediated rejection. Other causes
included acute ABMR (one case); recurrence of
glomerular disease (four cases); and sepsis (one case).
Twenty-nine grafts failed at five years. The relative risk
of death-censored five-year graft failure in pretreatment
C3d-positive cases was 2.52 (95% CI 1.29–4.91). The
difference in survival proportions for C3d-positive DSA
group at five years was  0.39 (95% CI  1, 0.686).
The association of pretreatment C3d-positive DSA
with renal allograft survival was investigated in a multi-
variable Cox proportional hazard analysis, using the
three models, as shown in Table 2. In Model 1 with
IgG values taken as a continuous variable, the presence
of pretreatment C3d-positive DSA was associated with
worse graft survival, hazard ratio 3.29 95%CI 1.37–7.86
(P = 0.007) (Table 2) (Fig. 1).
In model 2, IgG DSA MFI was categorized
into ≥ 8000 and < 8000. Sixty-five patients had pre-
treatment IgG DSA MFI> 8000, of whom forty-three
were C3d-positive. Of seventy-four patients who had
Table 1. Baseline characteristics and outcomes
Characteristics (n) All patients Pretreatment C3d positive Pretreatment C3d negative P-value*
Number of patients 139 52/139 87/139
Age, mean (SD) 42 (11.38) 38 (9.7) 44 (11.8) 0.003
Gender, male, n (%) 50 (36) 25 (48) 25 (29) 0.021
Previous transplantation, n (%) 88 (63) 40 (77) 48 (55) 0.01
Dialysis years, median (IQR)
mean rank
8 (3–16) 14.5 (8–18.75)
80.15
7 (3 15)
63.93
0.02
Mismatch, (A, B and DR) median (IQR)
mean rank
3 (2–4) 3 (2–4.75)
78.12
3 (2–4)
5.15
0.06
DR mismatch, median (IQR)
mean rank
1 (1–1) 1 (1–1)
75.44
1 (1–1)
66.75
0.15
Basiliximab (%) 92 (66) 32 (62) 60 (69) 0.48
Alemtuzumab (%) 33 (24) 11 (21) 22 (25) 0.70
rATG (%) 14 (10) 9 (17) 5 (6) 0.06
Median highest IgG MFI, (IQR)
Mean rank
7192 (3713–12278 12679 (10003–16254)
100.92
4949 (2328–7912)
51.52
<0.001
DSA class I only, n (%) 54 (39) 7 (13) 47 (54) <0.001
DSA class II only, n (%) 27 (19) 16 (31) 11 (13) 0.014
Class I + II, n (%) 58 (42) 29 (56) 29(33) 0.013
Day 14 C3d + DSA, n (%) 37(34) 23(44) 14(16) <0.001
Early ABMR, n (%) 49 (35) 21 (40) 28 (32) 0.36
ACR, n (%) 16 (11) 5 (10) 13 (15) 0.44
Mixed rejection, n (%) 10 (7) 3 (6) 7 (8) 0.74
Graft loss, n (%) 35(25) 22(42) 13 (15) <0.001
*Statistical tests used: age-independent samples t-test, gender, previous transplants, immunosuppression, DSA class, ABMR,
ACR and graft loss—Pearson chi-square test. Dialysis years, mismatch and IgG DSA MFI—Mann–Whitney U-test.
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IgG DSA MFI levels < 8000, only nine were C3d-posi-
tive. Pretreatment C3d-positive DSA cases were associ-
ated with lower graft survival compared with C3d-
negative DSA cases, hazard ratio 2.98 (95%CI 1.29–
6.88) (P = 0.011) (Table 2).
In Model 3, IgG DSA MFI was categorized
into ≥ 5000 and < 5000. Ninety-one patients had pre-
treatment IgG DSA MFI> 5000 of whom forty-eight
were C3d-positive, and forty-eight patients had an IgG
DSA MFI < 5000 of which four were C3d-positive. Pre-
treatment C3d-positive DSA cases were associated with
lower graft survival compared with C3d-negative DSA
cases, hazard ratio 3.31 95% CI 1.45–7.58 (P = 0.004)
(Table 2).
In all the three models, pretreatment C3d-positive
DSAs were independently associated with poor renal
allograft survival. IgG DSA was not significantly related
to graft survival in any of these models. Previous kidney
transplantation and ESRD duration were other indepen-
dent significant factors.
Subgroup analysis
C3d-positive DSA and graft survival in flow cross-match-positive
patients
Of 139 cases, twenty-six were CDC-positive. Forty cases
did not have CDC tested; hence, we looked at seventy-
three cases that were only FC positive as a subgroup to
explore sub-stratification using C3d. Eleven grafts failed
over the study period in this group. C3d-positive DSA
presents in seventeen cases.
The death-censored graft survival at five years in
C3d-positive DSA cases were lower at 64.5% compared
with 90.7% in C3d-negative DSA cases. The relative risk
of five-year graft failure was 3.74 (95%CI 1.12, 12.49).
The difference in survival proportions for C3d-positive
DSA group at five years was  0.25 (0.53, 0.014).
In the multivariate cox proportional hazards analysis
(Model 1), C3d-positive DSA cases were associated with
lower graft survival compared with C3d-negative DSA
cases. The hazard ratio was 9.8 (95%CI 1.6, 59.4).
(Fig. 2).
Graft survival according to pretreatment C3d-positive DSA HLA
class
Of 139 cases, IgG HLA class I DSAs were present in one
hundred and eleven cases, and IgG HLA class II DSAs
were present in eighty-six cases. Sixty-one cases had
both HLA classes I and II IgG DSAs. Fifty-two casesT
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had either HLA class I, HLA class II or both HLA
classes of pretreatment C3d-positive DSAs. HLA class I
C3d-positive DSA only were present in fifteen cases,
HLA class II C3d-positive DSA only was present in
twenty-nine cases and both HLA classes I and II C3d-
positive DSAs were present in four cases. Of the fifteen
HLA class I C3d-positive DSA cases, four grafts failed
over five years.
In Kaplan–Meier survival analysis, death-censored
graft survival at five years in cases with pretreatment
HLA class I C3d-positive DSA was marginally lower at
73.3% compared with 75.5% in HLA class I C3d-nega-
tive DSA cases (Fig. 3). The relative risk of death-cen-
sored five-year graft failure was 1.06 (95%CI 0.33, 3.42).
In Kaplan–Meier survival analysis, the death-censored
graft survival probability at five years in the class II
C3d-positive DSA cases was 60.7% compared with
80.6% in class II C3d-negative DSA cases (Fig. 4) with
the relative risk of 2.02 (95% CI 1.04–3.94).
Figure 1 Adjusted survival analysis of entire cohort with IgG DSA
MFI as continuous variable (Model 1). Death-censored five-year sur-
vival probability of graft in C3d-positive DSA group was lower at
59.6% compared with 84% in the C3d-negative DSA group. Hazard
ratio of 3.29 (95%CI 1.37–7.86)
Figure 2 Adjusted survival analysis of FC cross-match patients
including IgG DSA MFI as continuous variable (Model 1).Death-cen-
sored five-year survival probability of C3d-positive DSA cases were
lower at 64.8% compared with 90.6% in the C3d-negative DSA
cases. Hazard ratio of 9.8 (95%CI 1.6, 59.4)
Figure 3 Kaplan–Meier analysis: death-censored five-year survival
probability of class I C3d-positive DSA cases was marginally lower at
73.3% compared with 75.5% in class I C3d-negative DSA cases. Rel-
ative risk of graft failure was 1.06 (95% CI 0.33, 3.42)
Figure 4 Kaplan–Meier analysis: death-censored five-year survival
probability of class II C3d-positive DSA cases was lower at 60.7%
compared with 80.6% in class II C3d-negative DSA cases. Relative
risk of graft failure was 2.02 (95% CI 1.04, 3.94)
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In Kaplan–Meier survival analysis, the death-censored
graft survival probability at five years with both class I
and II C3d + DSA was lower at 50% compared with
80.7% in rest of the cases (Fig. 5)with the relative risk
of 2.05 (95%CI 0.73, 5.78).
Persistent C3d-positive DSAs and death-censored graft survival
analysis
One hundred eleven cases with both pretreatment and
Day 14 samples were studied. C3d status at pretreat-
ment and Day 14 were as follows. Fifty-seven cases had
C3d-negative DSA for both pretreatment and on Day
14 sample; twenty-four cases had both pretreatment and
Day 14 C3d-positive DSA; Sixteen cases had pretreat-
ment C3d-positive DSA but negative on Day 14, and
fourteen cases had negative pretreatment but C3d-posi-
tive DSA on Day 14.
In the Kaplan–Meier survival analysis, death-censored
five-year graft survival was worse in cases with both
pretreatment and Day 14 C3d-positive DSAs (43.5%)
compared with cases with both pretreatment and Day
14 C3d-negative DSAs (87.2%) (log-rank P = <0.001)
(Figure S1).
In the death-censored five-year graft survival analysis,
cases with pretreatment and Day 14 C3d-positive DSAs
were associated with worse five-year graft survival of
45.5% compared with 87.2% in cases with pretreatment
and Day14 C3d-negative DSAs (Fig. 7). The relative risk
of graft failure was 4.25 (95%CI 1.79, 10.09).
The relative risk of death-censored five-year graft
failure, according to C3d status, is presented in
Fig. 6. There were mainly four categories. In cases
with pretreatment C3d-positive DSA and Day 14
C3d-negative DSA compared to cases with pretreat-
ment and Day 14, C3d-negative DSA was 2.07 (95%
CI 0.59, 7.28); the relative risk of five-year graft fail-
ure in cases with pretreatment C3d-negative and Day
14 C3d-positive DSA compared to cases with pre-
treatment and Day 14 C3d-negative DSA was 2.03
(95%CI 0.58, 7.12).
In a multivariable Cox proportional hazard analysis
(Model1), cases with pretreatment and Day 14 C3d-posi-
tive DSA were associated with lower renal allograft sur-
vival compared with pretreatment and Day 14 C3d-
negative DSA cases. The hazard ratio was 4.56 (95%CI
1.46–14.39, P = 0.009) (Table 3). Models 2 and 3 had
similar results (data not included, available if necessary).
Discussion
This multicentre study illustrates the role of C3d assay in
the sub-stratification of graft survival risk in cross-
match-positive cases, for the first time. C3d assay was
able to clearly define groups with better outcome among
moderate to high immunological risk cases (Fig. 6). The
best graft survival is seen in patients with C3d-negative
DSA at both pretreatment and Day 14 (Fig. 7), which is
comparable to five-year graft survivals in deceased-donor
transplants in the United Kingdom. However, marginally
lower than standard living-donor transplants [9,41,42].
Figure 5 Kaplan–Meier analysis: death-censored five-year survival
probability of class I + II C3d-positive DSA cases was lower at 50%
compared with 80.7% in other cases. Relative risk of graft failure
was 2.05 (95% CI 0.73, 5.78)
Figure 6 Relative risks of death-
censored five-year graft failure as per
C3d-DSA status at pretreatment and
Day 14 compared with cases with
pretreatment and Day 14 C3d-
negative DSAs group
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The most inferior graft survival was found for those with
C3d-positive DSAs in both pretreatment and Day 14
sera. Thus, the lower risk cases can be predicted before
the transplant. In contrast, the highest risk cases can be
assessed if there is additional testing in the early post-
transplant period, long before the actual time of failure,
which indicates there is a potential for intervention in
the early post-transplant period.
Previous studies have only explored the role of com-
plement activation DSA assays in a predominantly lower
immunological risk group (DSA alone positive with
cross-match-negative cases). In a single-centre study, of
68 highly sensitized patients (twenty-one CDC cross-
match-positive patients) looked at the pretreatment risk
stratification using in vitro C4d deposition on SAB. Pres-
ence of pretransplant C4d-positive DSAs was associated
with acute AMR. One-, three- and five-year death-cen-
sored graft survival was also significantly lower in the
C4d-positive DSA patients compared with C4d-negative
DSA patients [43]. Similarly, other studies have shown
that in cross-match negative, sensitized patients with
complement-activating DSAs, as measured by C1q bind-
ing at the time of transplantation and/or post-transplan-
tation, are associated with poor renal allograft survival
[25,44,45]. A large study by Kamburova et al. concluded
that the presence of pretransplant C3d-positive DSAs was
associated with reduced renal allograft survival but did
not reach statistical significance [28]. Possible reason
could include the study cohort that comprised of cross-
match-negative DSA-positive cases (different from our
study cohort). Another possible explanation is considera-
tion of only pretransplant status of the DSAs. In other
studies on paediatric renal transplant population, com-
plement-activating DSAs in the post-transplant period
are a risk factor for graft failure [46,47].
Positive complement activation assays of DSAs uti-
lized at other time points (such as graft dysfunction or
ABMR) following transplantation were also associated
with inferior graft outcomes. Two comparable studies
have indicated that testing for complement-activating
DSA (C1q binding and C3d activation assays) at the
time of AMR predicts graft survival [23,25]. Similarly, a
recently published study from the deteriorating kidney
allograft function (DeKAF) investigators, in a cohort of
standard risk renal transplants, the results of a C3d
assay performed at the time of development of DSA
and graft dysfunction, predicted a higher risk of graft
failure in C3d-positive DSA group compared with C3d-
negative DSA group [27].
Thus, a common thread in these studies is that the
combination of pre- and postrenal transplantation test-
ing for complement-activating DSA can be of predictive
value, and their use, particularly in immunologically
high-risk cases, is becoming compelling. Which measure
of in vivo complement-activating potential, C1q binding
or C3d generation is superior, if at all, remains to be
proven; the study by Kim et al. and Lee et al. [24,48]
suggests the latter. Each assay measures different DSA
properties; C1q binding being dependant on Fc density
on the antibody target, while C3d generation quantifies
the full activation potential of the DSA (including Fc
cross-linking). C3 activation is the pivotal reaction of
the complement cascade, which leads to the production
of inflammatory mediators and direct tissue damage. As
such, the C3d assay would appear to be the more rele-
vant measure of DSA pathogenicity, which is why we
chose it for this study.
Table 3. In multivariable Cox proportional hazard model,
pretreatment and Day 14 C3d-positive DSAs were
associated with poor graft survival
Variable
Hazard
ratio 95% CI P-value
Age 0.80 0.09–6.80 0.840
Gender, female 1.45 0.55–3.81 0.45
Previous transplants 4.55 1.19–17.41 0.027
ESRD duration 0.09 0.01–0.63 0.016
Total mismatch 0.16 0.01–2.23 0.18
Early AMR 0.91 0.39–2.12 0.83
IgG DSA highest MFI 2.6 0.41–16.65 0.31
Both pretreatment
and Day14 C3d + DSA
4.56 1.46–14.40 0.009
Figure 7 Adjusted survival analysis including IgG DSA MFI as contin-
uous variable (Model 1). Death-censored five-year survival probability
of graft in pretreatment and Day 14 C3d-positive DSA group was
lower at 43.5% compared with 87.2% in the C3d-negative DSA
group. Hazard ratio of 4.56 (95%CI 1.46, 14.39)
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Also, we did not find a significant linear correlation
between C3d and higher IgG MFIs as compared to other
studies using C1q and IgG MFI [49,50] and C3d and
IgG MFI [38] (Figure S2). There remains to be proven
what an MFI value means for complement assay (either
C1q or C3d), as a higher MFI for complement split pro-
duct may not necessarily correlate in a linear fashion to
the quantity similar to IgG MFI. Thus, in this study
cohort, we have used only categorical/qualitative results.
It is established that complement-activating antibod-
ies, as detected by complement-dependent cytotoxicity
cross-match, are associated with a worse graft survival
[1]. However, the CDC assay is not always specific and
can identify other, non-HLA complement-activating
antibodies [50,51]. The availability of viable donor cells
still limits the CDC assay, and it is not always practical
to perform this assay on multiple occasions in the pre-
transplant and post-transplant periods. Correlation of
complement-activating DSA assays with CDC/FC cross-
matches is of interest. In recently published studies that
included samples from single centre of this cohort, a
positive C3d assay was shown to correlate with high
specificity, and a positive predictive value with positive
FC cross-match. However, sensitivity and negative pre-
dictive values were low [38,39]. A negative C3d assay
had a higher negative predictive value for CDC, and this
could be a useful surrogate marker for risk stratification,
as negative CDC cross-match is generally required at
the time of transplantation.
The flow cytometry cross-matches, although more
sensitive than CDC, have similar limitations to the CDC
assay. Typically, a positive pretransplantation cross-
match is discouraged due to the high risk of rejection
[52] and reduced graft survival [10,11]. Subgroup analy-
sis of FC cross-match patients in this study showed pre-
treatment C3d-positive DSAs were associated with lower
graft survival (Fig. 2). The findings are not entirely sur-
prising as one of the earlier studies that looked at the
utility of C4d-positive DSA in a cohort of highly sensi-
tized patients, and the presence of pretransplant C4d-
positive DSA in CDC cross-match patients was associ-
ated with worse graft survival compared with C4d-nega-
tive cohort [53]. The above findings demonstrate the
potential utility of C3d testing in cross-match-positive
patients.
In the subgroup analysis of graft survival based on
HLA class I and class II, cases with both HLA classes
C3d-positive DSAs had lower graft survival as compared
to other cases. The presence of only HLA class II C3d-
positive DSAs reached statistical significance. Limited
number of studies have looked at the HLA class of
complement-activating DSAs, and majority of these
studies are limited by relatively low numbers of patients.
In a recent study, de novo class II C3d-positive DSAs
were associated with higher rejection episodes and sig-
nificantly lower graft survival [24]. A study that looked
at the effect of C4d-positive DSA class on ABMR found
no significant difference [43]. However, a previous
study from the same group found lower graft survival
in the presence of HLA class I C4d-positive DSA but
not with HLA class II C4d-positive DSA [53]. Studies
that have looked at HLA class difference of DSAs on
allograft survival have not found statistical significance.
However, recent studies have demonstrated lower graft
survival with post-transplant de novo complement-acti-
vating HLA class II DSAs. [25,54,55].
The strengths of our study include multicentre valida-
tion of the C3d assay in a large cohort of cross-match-
positive patients. Also, patients received relatively
homogenous maintenance immunosuppression. How-
ever, this is a retrospective study and post-transplant Day
14 samples were not available for all 139 cases. Heteroge-
neous induction regimen may have affected the long-
term outcomes, although there was no statistical signifi-
cance between the groups (Table S4). It is also not possi-
ble to extrapolate optimal treatment strategies for early
post-transplant rising DSA levels with no graft dysfunc-
tion, as protocol biopsies were not performed. Further
mechanistic studies are required to explore the potential
for therapeutic options in the early post-transplant per-
iod. One of the pathways studied includes, inhibiting the
functions of active complement fragments such as C3d,
which has a role in augmenting B-cell-mediated alloim-
munity. [56]. Complement regulatory proteins, both
membrane-bound and circulating, play a role in the sus-
ceptibility of microvascular endothelial cells to comple-
ment-mediated damage. Augmenting the expression of
CD55, CD46 or CD59 on endothelial cells may reduce
the cytotoxicity of complement-activating antibodies
[57,58]. There are potential diagnostic and therapeutic
implications for identifying critical pathological path-
ways, including complement activation[59,60]. We spec-
ulate that rendering the C3d negative before a transplant
can result in better graft survival.
In conclusion, C3d assay enabled differentiation of
IgG antibodies with varying pathogenicity. Thus, it has
a potential role as an additional biomarker in further
risk assessment of transplant patients, especially in cases
with preformed DSAs and positive cross-match results
against their potential donors. Further prospective con-
trolled studies are required in high immunological risk
patients to establish the role of this approach.
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